Medicare Price Inflation Rebates Levied On 27 Part B Drugs In First Round; Pfizer Tops The List
Biden Administration releases first list of Part B drugs subject to inflation rebates; others to follow on quarterly basis. Medicare won’t invoice sponsors until 2025, but patients could see coinsurance reductions next month.
You may also be interested in...
President Biden’s Proposal To Expand Medicare Price Controls A Sign Of Things To Come
Even though it is unlikely that the policies will succeed in the currently divided Congress, the proposal reinforces industry’s concerns that once a foundation for Medicare price negotiation is established, policymakers will try to build on it.
Medicare Will Pick Up Tab Initially For Lower Part B Coinsurance Resulting From Price Inflation Rebates
Centers for Medicare and Medicaid Services ensures that providers won’t be short-changed if beneficiary cost sharing is lowered because price inflation rebates are applied against drug costs.
PBM Transparency Act Advances In Senate And It’s A Far Cry From The Rebate Rule
Bill aims to lower patient costs in part by engaging the US Federal Trade Commission to shed light on pharmacy benefit manager transactions with health plans, manufacturers and pharmacies.